aluates Reports

$ 0.0

Automative

Global Anti-VEGF Ophthalmic Drugs Market Research Report 2024

Published Date: August 2024

Report Code: QYRE-Auto-36W17888

BUY CHAPTERS

Global Anti-VEGF Ophthalmic Drugs Market Research Report 2024

Code: QYRE-Auto-36W17888

Report

August 2024

Pages:84

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Roche

Novartis

Coherus BioSciences

Regeneron Pharmaceuticals

Samsung Bioepis

Biocon Biologics

Chengdu Kanghong Pharmaceutical

Anti-VEGF Ophthalmic Drugs Market

Anti-VEGF ophthalmic drugs are medications specifically designed to inhibit vascular endothelial growth factor(VEGF),a protein that plays a critical role in promoting abnormal blood vessel growth in the eye.These drugs are used primarily in the treatment of eye conditions such as wet age-related macular degeneration(AMD),diabetic retinopathy,and macular edema,where excessive VEGF activity contributes to vision loss.

The global Anti-VEGF Ophthalmic Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.

North American market for Anti-VEGF Ophthalmic Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for Anti-VEGF Ophthalmic Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The major global manufacturers of Anti-VEGF Ophthalmic Drugs include Roche, Novartis, Coherus BioSciences, Regeneron Pharmaceuticals, Samsung Bioepis, Biocon Biologics, Chengdu Kanghong Pharmaceutical, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Anti-VEGF Ophthalmic Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-VEGF Ophthalmic Drugs.

The Anti-VEGF Ophthalmic Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Dose) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Anti-VEGF Ophthalmic Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Anti-VEGF Ophthalmic Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Anti-VEGF Ophthalmic Drugs Market Report

Report Metric	Details
Report Name	Anti-VEGF Ophthalmic Drugs Market
Segment by Type	Monoclonal Antibodies Fusion Proteins
Segment by Application	Age-related Macular Degeneration Diabetic Retinopathy Other
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Roche, Novartis, Coherus BioSciences, Regeneron Pharmaceuticals, Samsung Bioepis, Biocon Biologics, Chengdu Kanghong Pharmaceutical
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Anti-VEGF Ophthalmic Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Anti-VEGF Ophthalmic Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Anti-VEGF Ophthalmic Drugs Market report?

Ans: The main players in the Anti-VEGF Ophthalmic Drugs Market are Roche, Novartis, Coherus BioSciences, Regeneron Pharmaceuticals, Samsung Bioepis, Biocon Biologics, Chengdu Kanghong Pharmaceutical

What are the Application segmentation covered in the Anti-VEGF Ophthalmic Drugs Market report?

Ans: The Applications covered in the Anti-VEGF Ophthalmic Drugs Market report are Age-related Macular Degeneration, Diabetic Retinopathy, Other

What are the Type segmentation covered in the Anti-VEGF Ophthalmic Drugs Market report?

Ans: The Types covered in the Anti-VEGF Ophthalmic Drugs Market report are Monoclonal Antibodies, Fusion Proteins

Recommended Reports

Anti-VEGF & Ophthalmology

Ophthalmic Drugs Market

VEGF & Related Therapies

1 Anti-VEGF Ophthalmic Drugs Market Overview

1.1 Product Definition

1.2 Anti-VEGF Ophthalmic Drugs by Type

1.2.1 Global Anti-VEGF Ophthalmic Drugs Market Value Comparison by Type (2024-2030)

1.2.2 Monoclonal Antibodies

1.2.3 Fusion Proteins

1.3 Anti-VEGF Ophthalmic Drugs by Application

1.3.1 Global Anti-VEGF Ophthalmic Drugs Market Value by Application (2024-2030)

1.3.2 Age-related Macular Degeneration

1.3.3 Diabetic Retinopathy

1.3.4 Other

1.4 Global Anti-VEGF Ophthalmic Drugs Market Size Estimates and Forecasts

1.4.1 Global Anti-VEGF Ophthalmic Drugs Revenue 2019-2030

1.4.2 Global Anti-VEGF Ophthalmic Drugs Sales 2019-2030

1.4.3 Global Anti-VEGF Ophthalmic Drugs Market Average Price (2019-2030)

1.5 Assumptions and Limitations

2 Anti-VEGF Ophthalmic Drugs Market Competition by Manufacturers

2.1 Global Anti-VEGF Ophthalmic Drugs Sales Market Share by Manufacturers (2019-2024)

2.2 Global Anti-VEGF Ophthalmic Drugs Revenue Market Share by Manufacturers (2019-2024)

2.3 Global Anti-VEGF Ophthalmic Drugs Average Price by Manufacturers (2019-2024)

2.4 Global Key Players of Anti-VEGF Ophthalmic Drugs, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Anti-VEGF Ophthalmic Drugs, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Anti-VEGF Ophthalmic Drugs, Product Type & Application

2.7 Global Key Manufacturers of Anti-VEGF Ophthalmic Drugs, Date of Enter into This Industry

2.8 Global Anti-VEGF Ophthalmic Drugs Market Competitive Situation and Trends

2.8.1 Global Anti-VEGF Ophthalmic Drugs Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Anti-VEGF Ophthalmic Drugs Players Market Share by Revenue

2.8.3 Global Anti-VEGF Ophthalmic Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Anti-VEGF Ophthalmic Drugs Market Scenario by Region

3.1 Global Anti-VEGF Ophthalmic Drugs Market Size by Region: 2019 Versus 2023 Versus 2030

3.2 Global Anti-VEGF Ophthalmic Drugs Sales by Region: 2019-2030

3.2.1 Global Anti-VEGF Ophthalmic Drugs Sales by Region: 2019-2024

3.2.2 Global Anti-VEGF Ophthalmic Drugs Sales by Region: 2025-2030

3.3 Global Anti-VEGF Ophthalmic Drugs Revenue by Region: 2019-2030

3.3.1 Global Anti-VEGF Ophthalmic Drugs Revenue by Region: 2019-2024

3.3.2 Global Anti-VEGF Ophthalmic Drugs Revenue by Region: 2025-2030

3.4 North America Anti-VEGF Ophthalmic Drugs Market Facts & Figures by Country

3.4.1 North America Anti-VEGF Ophthalmic Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.4.2 North America Anti-VEGF Ophthalmic Drugs Sales by Country (2019-2030)

3.4.3 North America Anti-VEGF Ophthalmic Drugs Revenue by Country (2019-2030)

3.4.4 United States

3.4.5 Canada

3.5 Europe Anti-VEGF Ophthalmic Drugs Market Facts & Figures by Country

3.5.1 Europe Anti-VEGF Ophthalmic Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.5.2 Europe Anti-VEGF Ophthalmic Drugs Sales by Country (2019-2030)

3.5.3 Europe Anti-VEGF Ophthalmic Drugs Revenue by Country (2019-2030)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Anti-VEGF Ophthalmic Drugs Market Facts & Figures by Region

3.6.1 Asia Pacific Anti-VEGF Ophthalmic Drugs Market Size by Region: 2019 VS 2023 VS 2030

3.6.2 Asia Pacific Anti-VEGF Ophthalmic Drugs Sales by Region (2019-2030)

3.6.3 Asia Pacific Anti-VEGF Ophthalmic Drugs Revenue by Region (2019-2030)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Anti-VEGF Ophthalmic Drugs Market Facts & Figures by Country

3.7.1 Latin America Anti-VEGF Ophthalmic Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.7.2 Latin America Anti-VEGF Ophthalmic Drugs Sales by Country (2019-2030)

3.7.3 Latin America Anti-VEGF Ophthalmic Drugs Revenue by Country

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.7.7 Colombia

3.8 Middle East and Africa Anti-VEGF Ophthalmic Drugs Market Facts & Figures by Country

3.8.1 Middle East and Africa Anti-VEGF Ophthalmic Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.8.2 Middle East and Africa Anti-VEGF Ophthalmic Drugs Sales by Country (2019-2030)

3.8.3 Middle East and Africa Anti-VEGF Ophthalmic Drugs Revenue by Country

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Anti-VEGF Ophthalmic Drugs Sales by Type (2019-2030)

4.1.1 Global Anti-VEGF Ophthalmic Drugs Sales by Type (2019-2024)

4.1.2 Global Anti-VEGF Ophthalmic Drugs Sales by Type (2025-2030)

4.1.3 Global Anti-VEGF Ophthalmic Drugs Sales Market Share by Type (2019-2030)

4.2 Global Anti-VEGF Ophthalmic Drugs Revenue by Type (2019-2030)

4.2.1 Global Anti-VEGF Ophthalmic Drugs Revenue by Type (2019-2024)

4.2.2 Global Anti-VEGF Ophthalmic Drugs Revenue by Type (2025-2030)

4.2.3 Global Anti-VEGF Ophthalmic Drugs Revenue Market Share by Type (2019-2030)

4.3 Global Anti-VEGF Ophthalmic Drugs Price by Type (2019-2030)

5 Segment by Application

5.1 Global Anti-VEGF Ophthalmic Drugs Sales by Application (2019-2030)

5.1.1 Global Anti-VEGF Ophthalmic Drugs Sales by Application (2019-2024)

5.1.2 Global Anti-VEGF Ophthalmic Drugs Sales by Application (2025-2030)

5.1.3 Global Anti-VEGF Ophthalmic Drugs Sales Market Share by Application (2019-2030)

5.2 Global Anti-VEGF Ophthalmic Drugs Revenue by Application (2019-2030)

5.2.1 Global Anti-VEGF Ophthalmic Drugs Revenue by Application (2019-2024)

5.2.2 Global Anti-VEGF Ophthalmic Drugs Revenue by Application (2025-2030)

5.2.3 Global Anti-VEGF Ophthalmic Drugs Revenue Market Share by Application (2019-2030)

5.3 Global Anti-VEGF Ophthalmic Drugs Price by Application (2019-2030)

6 Key Companies Profiled

6.1 Roche

6.1.1 Roche Company Information

6.1.2 Roche Description and Business Overview

6.1.3 Roche Anti-VEGF Ophthalmic Drugs Sales, Revenue and Gross Margin (2019-2024)

6.1.4 Roche Anti-VEGF Ophthalmic Drugs Product Portfolio

6.1.5 Roche Recent Developments/Updates

6.2 Novartis

6.2.1 Novartis Company Information

6.2.2 Novartis Description and Business Overview

6.2.3 Novartis Anti-VEGF Ophthalmic Drugs Sales, Revenue and Gross Margin (2019-2024)

6.2.4 Novartis Anti-VEGF Ophthalmic Drugs Product Portfolio

6.2.5 Novartis Recent Developments/Updates

6.3 Coherus BioSciences

6.3.1 Coherus BioSciences Company Information

6.3.2 Coherus BioSciences Description and Business Overview

6.3.3 Coherus BioSciences Anti-VEGF Ophthalmic Drugs Sales, Revenue and Gross Margin (2019-2024)

6.3.4 Coherus BioSciences Anti-VEGF Ophthalmic Drugs Product Portfolio

6.3.5 Coherus BioSciences Recent Developments/Updates

6.4 Regeneron Pharmaceuticals

6.4.1 Regeneron Pharmaceuticals Company Information

6.4.2 Regeneron Pharmaceuticals Description and Business Overview

6.4.3 Regeneron Pharmaceuticals Anti-VEGF Ophthalmic Drugs Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Regeneron Pharmaceuticals Anti-VEGF Ophthalmic Drugs Product Portfolio

6.4.5 Regeneron Pharmaceuticals Recent Developments/Updates

6.5 Samsung Bioepis

6.5.1 Samsung Bioepis Company Information

6.5.2 Samsung Bioepis Description and Business Overview

6.5.3 Samsung Bioepis Anti-VEGF Ophthalmic Drugs Sales, Revenue and Gross Margin (2019-2024)

6.5.4 Samsung Bioepis Anti-VEGF Ophthalmic Drugs Product Portfolio

6.5.5 Samsung Bioepis Recent Developments/Updates

6.6 Biocon Biologics

6.6.1 Biocon Biologics Company Information

6.6.2 Biocon Biologics Description and Business Overview

6.6.3 Biocon Biologics Anti-VEGF Ophthalmic Drugs Sales, Revenue and Gross Margin (2019-2024)

6.6.4 Biocon Biologics Anti-VEGF Ophthalmic Drugs Product Portfolio

6.6.5 Biocon Biologics Recent Developments/Updates

6.7 Chengdu Kanghong Pharmaceutical

6.7.1 Chengdu Kanghong Pharmaceutical Company Information

6.7.2 Chengdu Kanghong Pharmaceutical Description and Business Overview

6.7.3 Chengdu Kanghong Pharmaceutical Anti-VEGF Ophthalmic Drugs Sales, Revenue and Gross Margin (2019-2024)

6.7.4 Chengdu Kanghong Pharmaceutical Anti-VEGF Ophthalmic Drugs Product Portfolio

6.7.5 Chengdu Kanghong Pharmaceutical Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Anti-VEGF Ophthalmic Drugs Industry Chain Analysis

7.2 Anti-VEGF Ophthalmic Drugs Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Anti-VEGF Ophthalmic Drugs Production Mode & Process

7.4 Anti-VEGF Ophthalmic Drugs Sales and Marketing

7.4.1 Anti-VEGF Ophthalmic Drugs Sales Channels

7.4.2 Anti-VEGF Ophthalmic Drugs Distributors

7.5 Anti-VEGF Ophthalmic Drugs Customers

8 Anti-VEGF Ophthalmic Drugs Market Dynamics

8.1 Anti-VEGF Ophthalmic Drugs Industry Trends

8.2 Anti-VEGF Ophthalmic Drugs Market Drivers

8.3 Anti-VEGF Ophthalmic Drugs Market Challenges

8.4 Anti-VEGF Ophthalmic Drugs Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Roche

Novartis

Coherus BioSciences

Regeneron Pharmaceuticals

Samsung Bioepis

Biocon Biologics

Chengdu Kanghong Pharmaceutical

List of Tables

Table 1. Global Anti-VEGF Ophthalmic Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)

Table 2. Global Anti-VEGF Ophthalmic Drugs Market Value by Application (2024-2030) & (US$ Million)

Table 3. Global Anti-VEGF Ophthalmic Drugs Market Competitive Situation by Manufacturers in 2023

Table 4. Global Anti-VEGF Ophthalmic Drugs Sales (K Dose) of Key Manufacturers (2019-2024)

Table 5. Global Anti-VEGF Ophthalmic Drugs Sales Market Share by Manufacturers (2019-2024)

Table 6. Global Anti-VEGF Ophthalmic Drugs Revenue (US$ Million) by Manufacturers (2019-2024)

Table 7. Global Anti-VEGF Ophthalmic Drugs Revenue Share by Manufacturers (2019-2024)

Table 8. Global Market Anti-VEGF Ophthalmic Drugs Average Price (US$/Dose) of Key Manufacturers (2019-2024)

Table 9. Global Key Players of Anti-VEGF Ophthalmic Drugs, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Anti-VEGF Ophthalmic Drugs, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Anti-VEGF Ophthalmic Drugs, Product Type & Application

Table 12. Global Key Manufacturers of Anti-VEGF Ophthalmic Drugs, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Anti-VEGF Ophthalmic Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-VEGF Ophthalmic Drugs as of 2023)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Anti-VEGF Ophthalmic Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 17. Global Anti-VEGF Ophthalmic Drugs Sales by Region (2019-2024) & (K Dose)

Table 18. Global Anti-VEGF Ophthalmic Drugs Sales Market Share by Region (2019-2024)

Table 19. Global Anti-VEGF Ophthalmic Drugs Sales by Region (2025-2030) & (K Dose)

Table 20. Global Anti-VEGF Ophthalmic Drugs Sales Market Share by Region (2025-2030)

Table 21. Global Anti-VEGF Ophthalmic Drugs Revenue by Region (2019-2024) & (US$ Million)

Table 22. Global Anti-VEGF Ophthalmic Drugs Revenue Market Share by Region (2019-2024)

Table 23. Global Anti-VEGF Ophthalmic Drugs Revenue by Region (2025-2030) & (US$ Million)

Table 24. Global Anti-VEGF Ophthalmic Drugs Revenue Market Share by Region (2025-2030)

Table 25. North America Anti-VEGF Ophthalmic Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 26. North America Anti-VEGF Ophthalmic Drugs Sales by Country (2019-2024) & (K Dose)

Table 27. North America Anti-VEGF Ophthalmic Drugs Sales by Country (2025-2030) & (K Dose)

Table 28. North America Anti-VEGF Ophthalmic Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 29. North America Anti-VEGF Ophthalmic Drugs Revenue by Country (2025-2030) & (US$ Million)

Table 30. Europe Anti-VEGF Ophthalmic Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 31. Europe Anti-VEGF Ophthalmic Drugs Sales by Country (2019-2024) & (K Dose)

Table 32. Europe Anti-VEGF Ophthalmic Drugs Sales by Country (2025-2030) & (K Dose)

Table 33. Europe Anti-VEGF Ophthalmic Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 34. Europe Anti-VEGF Ophthalmic Drugs Revenue by Country (2025-2030) & (US$ Million)

Table 35. Asia Pacific Anti-VEGF Ophthalmic Drugs Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 36. Asia Pacific Anti-VEGF Ophthalmic Drugs Sales by Region (2019-2024) & (K Dose)

Table 37. Asia Pacific Anti-VEGF Ophthalmic Drugs Sales by Region (2025-2030) & (K Dose)

Table 38. Asia Pacific Anti-VEGF Ophthalmic Drugs Revenue by Region (2019-2024) & (US$ Million)

Table 39. Asia Pacific Anti-VEGF Ophthalmic Drugs Revenue by Region (2025-2030) & (US$ Million)

Table 40. Latin America Anti-VEGF Ophthalmic Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Latin America Anti-VEGF Ophthalmic Drugs Sales by Country (2019-2024) & (K Dose)

Table 42. Latin America Anti-VEGF Ophthalmic Drugs Sales by Country (2025-2030) & (K Dose)

Table 43. Latin America Anti-VEGF Ophthalmic Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 44. Latin America Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country (2019-2024)

Table 45. Middle East and Africa Anti-VEGF Ophthalmic Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 46. Middle East and Africa Anti-VEGF Ophthalmic Drugs Sales by Country (2019-2024) & (K Dose)

Table 47. Middle East and Africa Anti-VEGF Ophthalmic Drugs Sales by Country (2025-2030) & (K Dose)

Table 48. Middle East and Africa Anti-VEGF Ophthalmic Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 49. Middle East and Africa Anti-VEGF Ophthalmic Drugs Revenue by Country (2025-2030) & (US$ Million)

Table 50. Global Anti-VEGF Ophthalmic Drugs Sales (K Dose) by Type (2019-2024)

Table 51. Global Anti-VEGF Ophthalmic Drugs Sales (K Dose) by Type (2025-2030)

Table 52. Global Anti-VEGF Ophthalmic Drugs Sales Market Share by Type (2019-2024)

Table 53. Global Anti-VEGF Ophthalmic Drugs Sales Market Share by Type (2025-2030)

Table 54. Global Anti-VEGF Ophthalmic Drugs Revenue (US$ Million) by Type (2019-2024)

Table 55. Global Anti-VEGF Ophthalmic Drugs Revenue (US$ Million) by Type (2025-2030)

Table 56. Global Anti-VEGF Ophthalmic Drugs Revenue Market Share by Type (2019-2024)

Table 57. Global Anti-VEGF Ophthalmic Drugs Revenue Market Share by Type (2025-2030)

Table 58. Global Anti-VEGF Ophthalmic Drugs Price (US$/Dose) by Type (2019-2024)

Table 59. Global Anti-VEGF Ophthalmic Drugs Price (US$/Dose) by Type (2025-2030)

Table 60. Global Anti-VEGF Ophthalmic Drugs Sales (K Dose) by Application (2019-2024)

Table 61. Global Anti-VEGF Ophthalmic Drugs Sales (K Dose) by Application (2025-2030)

Table 62. Global Anti-VEGF Ophthalmic Drugs Sales Market Share by Application (2019-2024)

Table 63. Global Anti-VEGF Ophthalmic Drugs Sales Market Share by Application (2025-2030)

Table 64. Global Anti-VEGF Ophthalmic Drugs Revenue (US$ Million) by Application (2019-2024)

Table 65. Global Anti-VEGF Ophthalmic Drugs Revenue (US$ Million) by Application (2025-2030)

Table 66. Global Anti-VEGF Ophthalmic Drugs Revenue Market Share by Application (2019-2024)

Table 67. Global Anti-VEGF Ophthalmic Drugs Revenue Market Share by Application (2025-2030)

Table 68. Global Anti-VEGF Ophthalmic Drugs Price (US$/Dose) by Application (2019-2024)

Table 69. Global Anti-VEGF Ophthalmic Drugs Price (US$/Dose) by Application (2025-2030)

Table 70. Roche Company Information

Table 71. Roche Description and Business Overview

Table 72. Roche Anti-VEGF Ophthalmic Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)

Table 73. Roche Anti-VEGF Ophthalmic Drugs Product

Table 74. Roche Recent Developments/Updates

Table 75. Novartis Company Information

Table 76. Novartis Description and Business Overview

Table 77. Novartis Anti-VEGF Ophthalmic Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)

Table 78. Novartis Anti-VEGF Ophthalmic Drugs Product

Table 79. Novartis Recent Developments/Updates

Table 80. Coherus BioSciences Company Information

Table 81. Coherus BioSciences Description and Business Overview

Table 82. Coherus BioSciences Anti-VEGF Ophthalmic Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)

Table 83. Coherus BioSciences Anti-VEGF Ophthalmic Drugs Product

Table 84. Coherus BioSciences Recent Developments/Updates

Table 85. Regeneron Pharmaceuticals Company Information

Table 86. Regeneron Pharmaceuticals Description and Business Overview

Table 87. Regeneron Pharmaceuticals Anti-VEGF Ophthalmic Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)

Table 88. Regeneron Pharmaceuticals Anti-VEGF Ophthalmic Drugs Product

Table 89. Regeneron Pharmaceuticals Recent Developments/Updates

Table 90. Samsung Bioepis Company Information

Table 91. Samsung Bioepis Description and Business Overview

Table 92. Samsung Bioepis Anti-VEGF Ophthalmic Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)

Table 93. Samsung Bioepis Anti-VEGF Ophthalmic Drugs Product

Table 94. Samsung Bioepis Recent Developments/Updates

Table 95. Biocon Biologics Company Information

Table 96. Biocon Biologics Description and Business Overview

Table 97. Biocon Biologics Anti-VEGF Ophthalmic Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)

Table 98. Biocon Biologics Anti-VEGF Ophthalmic Drugs Product

Table 99. Biocon Biologics Recent Developments/Updates

Table 100. Chengdu Kanghong Pharmaceutical Company Information

Table 101. Chengdu Kanghong Pharmaceutical Description and Business Overview

Table 102. Chengdu Kanghong Pharmaceutical Anti-VEGF Ophthalmic Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)

Table 103. Chengdu Kanghong Pharmaceutical Anti-VEGF Ophthalmic Drugs Product

Table 104. Chengdu Kanghong Pharmaceutical Recent Developments/Updates

Table 105. Key Raw Materials Lists

Table 106. Raw Materials Key Suppliers Lists

Table 107. Anti-VEGF Ophthalmic Drugs Distributors List

Table 108. Anti-VEGF Ophthalmic Drugs Customers List

Table 109. Anti-VEGF Ophthalmic Drugs Market Trends

Table 110. Anti-VEGF Ophthalmic Drugs Market Drivers

Table 111. Anti-VEGF Ophthalmic Drugs Market Challenges

Table 112. Anti-VEGF Ophthalmic Drugs Market Restraints

Table 113. Research Programs/Design for This Report

Table 114. Key Data Information from Secondary Sources

Table 115. Key Data Information from Primary Sources

Table 116. Authors List of This Report

List of Figures

Figure 1. Product Picture of Anti-VEGF Ophthalmic Drugs

Figure 2. Global Anti-VEGF Ophthalmic Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global Anti-VEGF Ophthalmic Drugs Market Share by Type: 2023 & 2030

Figure 4. Monoclonal Antibodies Product Picture

Figure 5. Fusion Proteins Product Picture

Figure 6. Global Anti-VEGF Ophthalmic Drugs Market Value by Application (2024-2030) & (US$ Million)

Figure 7. Global Anti-VEGF Ophthalmic Drugs Market Share by Application: 2023 & 2030

Figure 8. Age-related Macular Degeneration

Figure 9. Diabetic Retinopathy

Figure 10. Other

Figure 11. Global Anti-VEGF Ophthalmic Drugs Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 12. Global Anti-VEGF Ophthalmic Drugs Market Size (2019-2030) & (US$ Million)

Figure 13. Global Anti-VEGF Ophthalmic Drugs Sales (2019-2030) & (K Dose)

Figure 14. Global Anti-VEGF Ophthalmic Drugs Average Price (US$/Dose) & (2019-2030)

Figure 15. Anti-VEGF Ophthalmic Drugs Report Years Considered

Figure 16. Anti-VEGF Ophthalmic Drugs Sales Share by Manufacturers in 2023

Figure 17. Global Anti-VEGF Ophthalmic Drugs Revenue Share by Manufacturers in 2023

Figure 18. Global 5 and 10 Largest Anti-VEGF Ophthalmic Drugs Players: Market Share by Revenue in Anti-VEGF Ophthalmic Drugs in 2023

Figure 19. Anti-VEGF Ophthalmic Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 20. Global Anti-VEGF Ophthalmic Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Figure 21. North America Anti-VEGF Ophthalmic Drugs Sales Market Share by Country (2019-2030)

Figure 22. North America Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country (2019-2030)

Figure 23. United States Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 24. Canada Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 25. Europe Anti-VEGF Ophthalmic Drugs Sales Market Share by Country (2019-2030)

Figure 26. Europe Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country (2019-2030)

Figure 27. Germany Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 28. France Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 29. U.K. Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 30. Italy Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 31. Russia Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 32. Asia Pacific Anti-VEGF Ophthalmic Drugs Sales Market Share by Region (2019-2030)

Figure 33. Asia Pacific Anti-VEGF Ophthalmic Drugs Revenue Market Share by Region (2019-2030)

Figure 34. China Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 35. Japan Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 36. South Korea Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 37. India Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 38. Australia Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 39. China Taiwan Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 40. Southeast Asia Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 41. Latin America Anti-VEGF Ophthalmic Drugs Sales Market Share by Country (2019-2030)

Figure 42. Mexico Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 43. Brazil Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 44. Argentina Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 45. Colombia Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 46. Middle East and Africa Anti-VEGF Ophthalmic Drugs Sales Market Share by Country (2019-2030)

Figure 47. Middle East and Africa Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country (2019-2030)

Figure 48. Turkey Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 49. Saudi Arabia Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 50. UAE Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 51. Global Sales Market Share of Anti-VEGF Ophthalmic Drugs by Type (2019-2030)

Figure 52. Global Revenue Market Share of Anti-VEGF Ophthalmic Drugs by Type (2019-2030)

Figure 53. Global Anti-VEGF Ophthalmic Drugs Price (US$/Dose) by Type (2019-2030)

Figure 54. Global Sales Market Share of Anti-VEGF Ophthalmic Drugs by Application (2019-2030)

Figure 55. Global Revenue Market Share of Anti-VEGF Ophthalmic Drugs by Application (2019-2030)

Figure 56. Global Anti-VEGF Ophthalmic Drugs Price (US$/Dose) by Application (2019-2030)

Figure 57. Anti-VEGF Ophthalmic Drugs Value Chain

Figure 58. Anti-VEGF Ophthalmic Drugs Production Process

Figure 59. Channels of Distribution (Direct Vs Distribution)

Figure 60. Bottom-up and Top-down Approaches for This Report

Figure 61. Data Triangulation

Figure 62. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Anti VEGT Drugs Market Research Report 2024

Global Monoclonal Antibody Anti VEGF Ophthalmic Drugs Market Research Report 2024

Global Anti VEGF Intravitreal Drugs Market Research Report 2024

Global Single target Anti VEGF Drugs Market Research Report 2024

Global Anti VEGF Drugs for Angiogenesis related Disease Market Research Report 2024

Global Fusion Protein Anti VEGF Ophthalmic Drugs Market Research Report 2024

Global VEGF A Inhibitor Market Research Report 2024

Global VEGF Inhibitors Market Research Report 2024

Global Anti VEGF Therapeutic Market Research Report 2025

Global Anti Vascular Endothelial Growth Factor Therapeutic Market Research Report 2025

Global Intravitreal Injection of Anti VEGF Drugs Market Research Report 2024

Global Anti angiogenic Ophthalmic Agent Market Research Report 2024

Global VEGF Inhibitors for Cancer Market Research Report 2024

Anti vascular Endothelial Growth Factor Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Anti VEGF Therapy for Cancer Market Research Report 2024

Global Anti VEGF Drugs for the Treatment of Wet AMD Market Research Report 2024

Global Angiogenesis Therapeutic Agent Market Research Report 2024

VEGF Inhibitor Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Vascular Endothelial Growth Factor VEGF Inhibitors Market Insights Forecast to 2030

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions